Author

Maarten C. J. Anderegg

Observed names: M C J Anderegg, M. Anderegg, M. C. Anderegg, M. C. J Anderegg, M. C. J. Anderegg, M.C.J. Anderegg, Maarten Anderegg, Maarten C J Anderegg, Maarten C. Anderegg, Maarten C.J. Anderegg, Maarten CJ Anderegg

Institutions: Amsterdam UMC Location University of Amsterdam, Cancer Center Amsterdam

Observed institutions: University Medical Center Groningen, Harvard University, University of Groningen, Royal Victoria Infirmary, Amsterdam UMC Location University of Amsterdam, Massachusetts General Hospital, Amsterdam University Medical Centers, Cancer Center Amsterdam, Amsterdam Gastroenterology Endocrinology Metabolism, University of Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam

OpenAlex ID: A5113778005

The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis

2016 · Emil ter Veer, Nadia Haj Mohammad, et al. · JNCI Journal of the National Cancer Institute · 122

A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cell–Delivered TRAIL in Experimental Glioma Models

2010 · Tugba Bagci-Onder, Hiroaki Wakimoto, et al. · Cancer Research · 106

PDF

Effect of goal-directed therapy on outcome after esophageal surgery: A quality improvement study

2017 · Denise P. Veelo, Mark I. van Berge Henegouwen, et al. · PLoS ONE · 57

PDF

International Survey on the Management of Anastomotic Leakage After Esophageal Resection

2018 · Eliza R.C. Hagens, Maarten C.J. Anderegg, et al. · The Annals of Thoracic Surgery · 47

Prognostic Significance of the Location of Lymph Node Metastases in Patients With Adenocarcinoma of the Distal Esophagus or Gastroesophageal Junction

2016 · Maarten C. J. Anderegg, Sjoerd M. Lagarde, et al. · Annals of Surgery · 47

Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma

2017 · M. C. J. Anderegg, P. C. van der Sluis, et al. · Annals of Surgical Oncology · 46

PDF

Burden of spousal caregivers of stage II and III esophageal cancer survivors 3 years after treatment with curative intent

2015 · N. Haj Mohammad, A. W. Walter, et al. · Supportive Care in Cancer · 44

PDF

Treatment strategies in recurrent esophageal or junctional cancer

2017 · R. Butter, S. M. Lagarde, et al. · Diseases of the Esophagus · 36

PDF

18F-FDG PET-CT after Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients to Optimize Surgical Decision Making

2015 · Maarten C. J. Anderegg, Elisabeth J. de Groof, et al. · PLoS ONE · 31

PDF

Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis

2017 · Emil ter Veer, Lok Lam Ngai, et al. · Scientific Reports · 29

PDF

Minimally invasive surgery for oesophageal cancer

2013 · Maarten C.J. Anderegg, Suzanne S. Gisbertz, et al. · Best Practice & Research Clinical Gastroenterology · 28

Evaluating the Effect of Therapeutic Stem Cells on TRAIL Resistant and Sensitive Medulloblastomas

2012 · Irina Nesterenko, Simone Wanningen, et al. · PLoS ONE · 25

PDF

Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes

2015 · L. E. A. M. M. Spierings, S. M. Lagarde, et al. · Annals of Surgical Oncology · 24

Learning inguinal hernia repair? A survey of current practice and of preferred methods of surgical residents

2020 · T. Nazari, M. E. W. Dankbaar, et al. · Hernia · 12

PDF

Prognostic value of Mandard score and nodal status for recurrence patterns and survival after multimodal treatment of oesophageal adenocarcinoma

2024 · Sofie P G Henckens, Dajia Liu, et al. · British journal of surgery · 10

PDF

Patients with oesophageal cancer report elevated distress and problems yet do not have an explicit wish for referral prior to receiving their medical treatment plan

2016 · M. Jacobs, M. C. J Anderegg, et al. · Psycho-Oncology · 10

18F-FDG-PET/CT to Detect Pathological Complete Response After Neoadjuvant Treatment in Patients with Cancer of the Esophagus or Gastroesophageal Junction: Accuracy and Long-Term Implications

2023 · D. C. van der Aa, S. S. Gisbertz, et al. · Journal of Gastrointestinal Cancer · 3

PDF

1683TiP OMIT trial: omitting therapeutic lymph node dissection in patients with stage IIIB/C melanoma and major pathological response in the index lymph node after neoadjuvant immunotherapy

2025 · A.W. Schurink, J.A. van den Broek, et al. · Annals of Oncology · 1

Survival after pathologic complete response in patients with cancer of the esophagus or gastroesophageal junction.

2014 · Sjoerd M Lagarde, Maarten CJ Anderegg, et al. · Journal of Clinical Oncology · 1

Statin use and oncologic outcomes following neoadjuvant therapy for esophageal cancer

2026 · Dillen C. van der Aa, Maarten C. J. Anderegg, et al. · Journal of Thoracic Disease

Supplementary Table Legends 1-5 from A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cell–Delivered TRAIL in Experimental Glioma Models